Baiyang Medical Group Partners with MSD to Advance Immuno-Oncology and Promote Cancer as a Chronic Disease

VCBeat (WeChat ID: vcbeat) has learned that,2018Year10Month12Day, Baiyang Pharmaceutical Group and Merck Sharp & Dohme (China) Co., Ltd. announced that they have established a partnership. To meet the urgent needs of cancer patients for high-quality medical services and disease management, both parties will leverage their respective strengths in oncology treatment to explore and implement effective whole-course disease management for cancer patients, thereby advancing the clinical application of cancer immunotherapy.

Recently，2018 Nobel Prize in Physiology or MedicineAwardAmerican immunologist James· James P. Allison and Japanese immunologist Tasuku Honjo, in recognition of their contributions to cancer immunotherapy, highlighting the significance of tumor immunotherapy.Si Lu, Chief Physician at Peking University Cancer Hospital, stated,Cancer immunotherapy, represented by PD-1/L1 monoclonal antibodies, marks a generational leap. Immunotherapy has saved the lives of many patients with advanced-stage cancer, and numerous new immunotherapeutic agents are expected to emerge globally within the next 3–5 years. In ChinaalsoMany immunotherapy drugs will be gradually launched on the market.

With its anti-cancerGuangSpectrum,Persistentand lower side effects,MoSandEastPembrolizumab Injection (Keytruda, Chinese brand name Keyruida）WaitPD-1/PD-L1Monoclonal AntibodyMedicines have become a globalOncology DrugsThe Shining Star of the Market.Keytruda is one of the representative drugs in current immuno-oncology therapy, due to2015Gained Fame by Treating Former U.S. President Carter’s Malignant Melanoma，Has beenThe FDA has approved its use for eight types of tumors, including non-small cell lung cancer, gastric cancer, cervical cancer, and malignant melanoma, covering 12 indications.

BaiyangIntelligent Oncology Treatment: Comprehensive SolutionsDedicated to transforming cancer into a chronic disease,This protocolandMerck & Co.'sCombination of tumor immunotherapy regimens willIt brings new possibilities for reshaping the diagnosis and treatment model for cancer patients, offering more precise care and an improved experience. Baiyang will provide comprehensive support services in decision support for oncology treatment plans, drug accessibility during treatment, drug infusion, and patient management, enabling more Chinese cancer patients to conveniently accessKeytrudaImmunotherapy Regimen.

Fu Gang, Chairman of Baiyang Pharmaceutical GroupMentioned that artificial intelligence will reconstruct medical scenarios, Baiyang's intelligent tumor treatment solutionThe plan will receiveWatson Oncology Solution's Decision Support,WatsonCompanion diagnostics for genetic solutions and accessibility programs for easy-refill medications to enable the chronic disease management of cancer.BaiyangThrough an intelligent, comprehensive solution for tumor treatmentSupportMerck ImmunologyMedicineBenefits andChinathe vast number of cancer patients,Comprehensive Promotion of OncologyImmunotherapy DrugsClinical Applications and Value-Added Services，Bringing new possibilities and a better experience to the treatment of cancer patients.

InTreatmentDecision-making phase,With the help ofIBM WatsonAI Treatment Plan,Clinicians can develop more rational tumor immunotherapy regimens for patients; robust evidence-based medical data can help build confidence among both physicians and patients, thereby improving treatment efficiency and outcomes.As an Oncologist“Reliable Assistant”，WatsonPreviously atTrained at Memorial Sloan Kettering Cancer Center, a top U.S. cancer treatment institution, we provide patients with personalized, evidence-based treatment plans., andSupportableCategory 13For common cancer types, the alignment of the provided treatment regimens with those recommended by world-leading experts exceeds90%。To date,Watsonhas already been close to80reached a cooperation agreement with three Grade A tertiary hospitals, andPromisingImplemented in More Healthcare Institutions。

AboutDrug Accessibility Issues, Baiyang's Yifuzhen Third-Party Prescription Sharing PlatformAbilityEffectively connecting hospitals, patients, and pharmacies, the platform is patient-centric, collaborating with hospitals, health and family planning commissions, drug administration authorities, social security departments, and retail pharmacies.ImplementationInterconnectivity of Prescription Information from Medical Institutions, Medical Insurance Settlement Data, and Retail Drug Sales Information. The platformnot only addresses the issue of drug accessibility, but alsoAssist Physicians in Post-Consultation Patient Management。

As a key strategic partner of Baiyang, iKang Guobin’s offline high-end outpatient clinics will becomeKeytrudakey infusion sites. After the treatment plan is determined and drug accessibility issues are resolved, Baixiang’s cold-chain logistics deliver the medications to iKang’s infusion centers, where patients receive infusions administered by iKang’s professional physicians. Additionally, Baixiang Puti Huisheng Medical Laboratory Center provides value-added services for cancer patients, including tumor immuno-companion diagnostics, precision oncology testing, and systematic medical evaluation of tumors, through system-based testing, process-controlled testing, and intelligent testing.

To fully advance intelligent cancer treatment, Baiyang Pharmaceutical Group will also collaborate with Merck & Co. to exploreWatsonwithKeytrudacomprehensive promotion integration points, and connect both parties' resources in the oncology field to deepen multi-faceted cooperation with medical institutions and experts. Meanwhile, leveraging the Baiyang Smart Pharmacy Project, both parties will deepenKeytrudaRetail channel layout and patient service capabilities.

Mou Yanping, General Manager of Merck & Co.’s Oncology Business Division, stated:“Merck & Co., Inc. is actively seeking more strategic partners worldwide to develop combination therapies and achieve precision oncology, aiming for breakthrough advancements in the global cancer field. The vision of Merck’s Oncology Division is to provide innovative products and services to cancer patients worldwide, saving lives, extending and improving quality of life, and benefiting more patients.”